Oxyntomodulin
Endogenous glucagon-like peptide 1 and glucagon co-agonist peptide
37 Amino Acids · MW: ~4,200 Da
Amino Acids
37
Molecular Weight
~4,200 Da
Half-life
12-15 minutes
Research Score
4.4
Studies
80
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is Oxyntomodulin?
Oxyntomodulin is a naturally occurring proglucagon-derived peptide that activates GLP-1 and glucagon pathways. It is a key research tool for appetite suppression and energy balance studies in obesity.
Key Benefits & Mechanisms
reduces appetite
increases satiety
supports weight loss
improves postprandial metabolic signaling
Research Summary
Human studies showed acute reductions in food intake and modest weight loss, helping establish the GLP-1 and glucagon co-agonism concept. It remains a foundational peptide for obesity and satiety research.
Related Peptides
Cotadutide
MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist
Cotadutide is a synthetic oxyntomodulin analogue designed to engage both GLP-1 and glucagon receptors. It was developed to improve weight loss and metabolic markers in obesity and type 2 diabetes research.
Weight ManagementMazdutide
IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist
Mazdutide is a long-acting oxyntomodulin-inspired dual agonist being developed for obesity and metabolic disease. It is designed to drive clinically meaningful weight loss while improving glucose and lipid parameters.
Weight ManagementDulaglutide
Recombinant GLP-1 receptor agonist Fc fusion protein
Dulaglutide is a long-acting GLP-1 receptor agonist used primarily in type 2 diabetes. It consistently produces modest weight loss and is widely studied as a benchmark incretin mimetic.
Weight ManagementLixisenatide
Exendin-4-derived GLP-1 receptor agonist
Lixisenatide is a short-acting GLP-1 receptor agonist derived from exendin-4. It is best known for postprandial glucose control, with modest secondary weight loss in clinical use.
Weight Management